# To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

> **NCT01478490** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 28 (actual)

## Conditions studied

- Pharmacokinetics of Mirabegron
- Healthy Subjects

## Interventions

- **DRUG:** mirabegron
- **DRUG:** metoprolol

## Key facts

- **NCT ID:** NCT01478490
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-11
- **Final completion:** 2002-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478490, "To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01478490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*